SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Oliver & Co who wrote (5375)9/22/1998 12:49:00 PM
From: Steve Fancy  Read Replies (3) of 6136
 
Oliver, regarding Remume, that is my general feeling also based on general response to information so far. I have to ask myself though, If the possiblilties are as bleak as originally suggested, why did Johnson direct so much energy and cash in this direction. But then I remember AG3340 and the Oncology division whose target is apparently 85% of the 10% of macular degeneration patients.

Question, do you feel you've seen ample information on Remune to express confidently the future looks bleak, or is your position more of a wait and see? What type of data might convince you otherwise? Any idea when we expect further information on Remune trials?

Thanks,

sf

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News